Business
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV
About this update from Supernus Pharmaceuticals, Inc.
[{"type":"image","alt":"Supernus Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Supernus Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/e106c72a48ff432ec8d84873fc8164bb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1cawVaerzPmjsZf0nQ1wUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNg--/https://media.zenfs.com/en/globenewswire.com/e106c72a48ff432ec8d84873fc8164bb","width":300,"height":76}},"lazy":false},{"type":"text","content":"ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.","length":501,"tagName":"p"},{"type":"text","content":"Investors interested in arranging a meeting with company management during the conference should contact the Bank of America conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section of the Supernus Pharmaceuticals website at www.supernus.com/Investors. An archived replay of the webcasts will be available for 60 days on the Company's website following the conference.","length":477,"tagName":"p"},{"type":"text","content":"About Supernus Pharmaceuticals, Inc.","length":36,"tagName":"p"},{"type":"text","content":"Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.","length":166,"tagName":"p"},{"type":"text","content":"Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.","length":393,"tagName":"p"},{"...